- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07729384
A Study of Strengthening Teen Brain Resilience Using Music During Cancer Treatment
July 22, 2026 updated by: Mayo Clinic
Strengthening Teen Brain Resilience Using Music (STRUM) During Cancer Treatment: A Pilot Feasibility Trial
This clinical trial tests the feasibility and acceptability of the Strengthening Teen Brain Resilience Using Music (STRUM) intervention to improve radiation induced cognitive decline for adolescents undergoing radiation therapy for cancer treatment.
Adolescents treated with radiation therapy for cancer often experience persistent cognitive deficits and reduced brain resilience or the ability to preserve cognitive and emotional functioning despite stressors.
Musical instrument training has been shown to enhance memory, academic skills, and emotional well-being in youth.
Although guitars are often the most preferred instrument, ukuleles offer greater accessibility due to their simplicity, affordability, and suitability for younger users.
The STRUM intervention consists of virtual active music therapy ukulele lessons, which may be a feasible and acceptable way to improve radiation induced cognitive decline for adolescents undergoing radiation therapy for cancer treatment.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robert Bennett, PhD, RN
- Phone Number: 480-301-4394
- Email: bennett.robert@mayo.edu
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic in Arizona
-
Principal Investigator:
- C. Robert Bennett, PhD, RN
-
Contact:
- Robert Bennett, PhD, RN
- Phone Number: 480-301-4394
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged 12-17 years at the time of enrollment
- Receiving initial radiation therapy (RT) for cancer treatment with curative intent at the Mayo Clinic Arizona
- Able to provide assent
- Able to read and write in English
- Have access to an electronic device with videoconferencing capability
Exclusion Criteria:
- Less than three-month prognosis
- Past history of RT
- Self-reported visual, hearing, or cognitive impairment impeding the ability to complete the STRUM intervention
- Prior receipt of ukulele or guitar lessons
- Actively receiving musical instrument lessons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Supportive care (STRUM sessions)
Patients receive a ukulele, tuner, and songbook and attend virtually delivered ukulele lessons over 30 minutes each, once weekly, for 10 weeks.
Intervention sessions are structured with stair-stepping difficulty with each lesson concluding with learning a new song.
Ten optional supplemental video-recorded lessons (approximately 15 minutes each) will be available for patients to view asynchronously and use for independent practice between weekly sessions.
Patients are encouraged to practice their skills independently for at least 90 minutes per week.
At the conclusion of the study, patients may attend an optional virtual "Encore Concert Event" remotely, featuring audio-video clips compiled from participants' lessons.
|
Ancillary studies
Ancillary studies
Attend STRUM sessions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of eligible participants who consent to participate in this study (feasibility)
Time Frame: At time of enrollment
|
Feasibility defined as achieving a ≥ 70% consent rate among eligible participants.
|
At time of enrollment
|
|
Proportion of STRUM sessions completed (feasibility)
Time Frame: Up to 10 weeks
|
Participants will receive 10 weekly 30-minute virtual ukulele lessons over ten weeks.
Basic descriptive statistical analyses will be performed.
|
Up to 10 weeks
|
|
Average weekly practice minutes
Time Frame: Up to 10 weeks
|
Assessed by patient self-report.
Participants will be encouraged to practice their skills independently for at least 90 minutes per week.
Basic descriptive statistical analyses will be performed.
|
Up to 10 weeks
|
|
Percentage of participants who complete ≥ 90% of the measures at each timepoint (feasibility)
Time Frame: Baseline, week 6, week 12, week 20
|
Basic descriptive statistical analyses will be performed.
|
Baseline, week 6, week 12, week 20
|
|
Acceptability of the Strengthening Teen Brain Resilience Using Music (STRUM) intervention
Time Frame: Approximately 2 weeks following end of intervention (week 12)
|
Defined as mean Acceptability of Intervention Measure (AIM) score of ≥ 3/4, supported by exit interview feedback.
Basic descriptive statistical analyses will be performed.
The AIM is a study-specific measure that consists of 4 questions, each answered on a scale of 1 (completely disagree) to 5 (completely agree).
Higher scores indicate greater acceptability.
|
Approximately 2 weeks following end of intervention (week 12)
|
|
Participant perspective on meaningfulness of the STRUM intervention
Time Frame: Approximately 2 weeks following end of intervention (week 12)
|
Assessed by exit interview feedback.
Participants will complete semi-structured exit interviews (approximately 30-minute duration).
Exit interview transcripts will be analyzed and coded using thematic analyses.
Thematic findings will be used to refine the intervention design and delivery.
|
Approximately 2 weeks following end of intervention (week 12)
|
|
Change in brain resilience
Time Frame: Baseline, week 6, week 12, week 20
|
Assessed by cognitive testing using the BrainCheck Assess™ digital platform.
Each testing session should take approximately 15 minutes.
Standard aggregate scores range from 0-200 with lower scores generally suggesting greater cognitive impairment.
|
Baseline, week 6, week 12, week 20
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: C. Robert Bennett, PhD, RN, Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2026
Primary Completion (Estimated)
November 1, 2028
Study Completion (Estimated)
November 1, 2028
Study Registration Dates
First Submitted
July 22, 2026
First Submitted That Met QC Criteria
July 22, 2026
First Posted (Actual)
July 27, 2026
Study Record Updates
Last Update Posted (Actual)
July 27, 2026
Last Update Submitted That Met QC Criteria
July 22, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Therapeutics
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Complementary Therapies
- Patient Care
- Psychotherapy
- Behavioral Disciplines and Activities
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Sensory Art Therapies
- Interviews as Topic
- Music Therapy
Other Study ID Numbers
- 25-014110
- NCI-2026-03943 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Neoplasm
-
M.D. Anderson Cancer CenterTerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
Ronald LevyBristol-Myers SquibbCompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
University of California, San FranciscoCompletedIntegrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced CancerAdvanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterTerminatedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Refractory NeoplasmUnited States
Clinical Trials on Survey Administration
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHepatocellular CarcinomaUnited States
-
Thomas Jefferson UniversityWithdrawnMalignant Head and Neck NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Vascular NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMelanoma | COVID-19 InfectionUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)WithdrawnMelanoma | Breast Carcinoma | Lung Carcinoma | Colorectal Carcinoma | Community Practice | Solid NeoplasmUnited States